Determination of Residual Solvents in Pharmaceutical Preparations: Standards, Methods, and Regulator

Residual solvent determination is a critical quality control test for pharmaceutical preparations, verifying that volatile organic solvents carried over from API synthesis, excipient production, or formulation processes remain within safe exposure limits. Guided by ICH Q3C (R8), USP General Chapter 467, Ph. Eur. 2.4.24, and ChP General Chapter 0861, this article explains solvent classification, permitted daily exposure limits, headspace gas chromatography methodology, and practical considerations for testing finished dosage forms.

Technical Overview

Residual solvents are organic volatile chemicals that are used or produced in the manufacture of drug substances, excipients, or pharmaceutical preparations and are not completely removed by practical manufacturing techniques. In finished dosage forms, they may originate from the final purification steps of the active pharmaceutical ingredient (API), from solvent-based excipient production, or from formulation operations such as wet granulation, spray coating, film formation, and spray drying. Because many of these solvents exhibit genotoxicity, neurotoxicity, or environmental hazards, their levels must be controlled to protect patient safety.

The internationally harmonized framework for residual solvent control is established in ICH Q3C (R8), which is implemented in USP General Chapter 467, Ph. Eur. General Chapter 2.4.24, and the Chinese Pharmacopoeia (ChP) General Chapter 0861. The guideline adopts a risk-based, toxicity-driven classification system:

• Class 1 solvents: confirmed or strongly suspected human carcinogens and environmental hazards that must be avoided.
• Class 2 solvents: non-genotoxic animal carcinogens or solvents causing reversible toxicity, which are restricted by a permitted daily exposure (PDE).
• Class 3 solvents: solvents with low toxic potential that are generally limited to 5000 ppm (50 mg per day).

Acceptance limits are derived from the PDE using the relationship: concentration limit (ppm) = PDE (mg/day) × 1000 / maximum daily dose of the drug product (g/day). For products with a daily dose not exceeding 10 g, the tabulated concentration limits (Option 1) may be applied directly; for high-dose products, product-specific limits must be calculated (Option 2). Analytically, residual solvents in preparations are determined almost universally by static headspace gas chromatography with flame ionization detection (GC-FID), supported by confirmatory procedures and, where necessary, GC-MS identification.

Testing Samples

Residual solvent testing applies to virtually all finished dosage form categories. Sample handling and preparation strategies differ depending on the physical form and solubility of the product.

Oral Solid Dosage Forms

Tablets, film-coated tablets, capsules, granules, sachets, and powders represent the most common sample types. Coated products deserve particular attention because film-coating and granulation processes frequently employ ethanol, isopropanol, acetone, ethyl acetate, or methylene chloride, which can be retained in the coating layer or core. Samples are typically ground or used whole and dispersed in a suitable diluent before headspace analysis.

Liquid and Injectable Preparations

Oral solutions, syrups, suspensions, tinctures, and sterile injectables are tested for process solvents such as ethanol, acetone, and ethyl acetate that may persist after sterilization or concentration steps. Water-miscible liquid products can often be analyzed directly after dilution, while oily injectables require dilution in a high-boiling organic solvent such as dimethyl sulfoxide (DMSO) or N,N-dimethylformamide (DMF).

Semi-Solid and Topical Preparations

Ointments, creams, gels, and transdermal systems may retain solvents from polymer dissolution, adhesive casting, or patch manufacturing (for example, hexane, heptane, ethyl acetate, or toluene). These matrices usually require dissolution in DMSO or DMF with aggressive headspace equilibration to ensure quantitative release of the analytes.

Other Special Dosage Forms

Inhalation products, pellets for oral suspension, lyophilized powders, and drug-device combination products are tested according to their specific manufacturing history. Lyophilized products, in particular, can retain solvents such as tert-butanol used as a cryo- or lyoprotective agent.

Testing Items

The scope of testing is dictated by the known manufacturing process. If the solvents used in the API synthesis, excipient production, and formulation are documented, testing is targeted at those specific solvents. When process knowledge is incomplete, a general screen for Class 1 and Class 2 solvents is performed in accordance with USP 467 or ChP 0861.

Class 1 Solvents (To Be Avoided)

• Benzene — limit 2 ppm
• Carbon tetrachloride — limit 4 ppm
• 1,2-Dichloroethane — limit 5 ppm
• 1,1-Dichloroethene — limit 8 ppm
• 1,1,1-Trichloroethane — limit 1500 ppm

Class 2 Solvents (Restricted by PDE)

The ICH Q3C list contains approximately 27 Class 2 solvents. Representative concentration limits, based on a maximum daily dose of 10 g (Option 1), include:

• Methanol — 3000 ppm
• Acetonitrile — 410 ppm
• Dichloromethane (methylene chloride) — 600 ppm
• Chloroform — 60 ppm
• Hexane — 290 ppm
• Toluene — 890 ppm
• Xylene — 2170 ppm
• Cyclohexane — 3880 ppm
• N,N-Dimethylformamide — 880 ppm
• N,N-Dimethylacetamide — 1090 ppm
• N-Methylpyrrolidone — 530 ppm
• 1,4-Dioxane — 380 ppm
• Pyridine — 200 ppm
• Chlorobenzene — 360 ppm
• 2-Methoxyethanol and methylbutyl ketone — 50 ppm each

Class 3 Solvents (Low Toxic Potential)

Class 3 solvents include acetone, ethanol, isopropanol (2-propanol), 1-propanol, ethyl acetate, isopropyl acetate, butyl acetate, methyl acetate, 1-butanol, 2-butanol, 2-methyl-1-propanol, 3-methyl-1-butanol, 1-pentanol, pentane, heptane, methyl ethyl ketone, tert-butyl methyl ether, ethyl ether, DMSO, ethyl formate, formic acid, and acetic acid, among others. Where the general chapter permits, Class 3 content may be controlled by loss on drying when the result is low and the daily dose allows; otherwise, GC quantitation is required against the 5000 ppm limit.

Unlisted and Process-Specific Solvents

Solvents not listed in ICH Q3C (for example, certain process reagents or emerging green solvents) require a scientifically justified acceptance limit based on toxicological data, a documented PDE, or a threshold of toxicological concern approach before they can be used in commercial manufacture.

Testing Methods

Sample Preparation

Water-soluble preparations are dissolved or dispersed in purified water as the diluent. Water-insoluble products are dissolved in DMSO or DMF. A typical preparation places the equivalent of 0.1 to 1.0 g of sample into a 20 mL headspace vial with 5 to 10 mL of diluent; sodium chloride is frequently added to enhance partitioning of polar solvents into the gas phase. Vials are sealed immediately with PTFE-lined caps to prevent volatile loss.

Static Headspace GC-FID (Primary Method)

Static headspace sampling is the method of choice because it is solvent-free for the injector, minimizes matrix interference, and focuses on volatile analytes. Typical conditions aligned with USP 467 and ChP 0861 include:

• Headspace equilibration: 80 to 85 °C for 30 to 60 minutes, with loop and transfer line temperatures set 10 to 20 °C above the oven temperature.
• Chromatographic column A: 30 m × 0.32 mm fused silica capillary coated with a 6% cyanopropylphenyl / 94% dimethylpolysiloxane phase (USP G43), 1.8 µm film.
• Oven program: 40 °C held for 20 minutes, ramped at 10 °C/min to 240 °C, then held.
• Detector: flame ionization detector at approximately 250 °C.
• Quantitation: external standard method using system suitability standard solutions containing the solvents of interest at their concentration limits.

Two-Column Confirmation Strategy

Following USP 467 logic, Procedure A screening is performed on the G43-type column. If any observed peak exceeds its limit relative to the standard, Procedure B re-analysis is performed on a polyethylene glycol (USP G16) column with complementary selectivity to confirm the identity of the peak. Where matrix interference or co-elution persists, Procedure C uses modified chromatographic conditions or standard addition for accurate quantitation. A sample passes only when the confirmed level of each solvent is at or below its acceptance limit.

Direct Injection and GC-MS Techniques

High-boiling or poorly volatile solvents such as DMF, DMSO, N-methylpyrrolidone, ethylene glycol, sulfolane, and 2-ethoxyethanol exhibit poor headspace sensitivity and are better determined by direct liquid injection GC or dissolved-sample injection. GC-MS in electron ionization mode is employed to identify unknown or unexpected volatile peaks discovered during screening, using mass spectral library matching supported by retention index data.

Method Validation

Methods intended for batch release or regulatory submission are validated in accordance with ICH Q2 (R2), covering:

• Specificity: complete resolution of all target solvents from each other and from matrix peaks.
• Linearity: typically across 20% to 200% of the limit concentration, with correlation coefficient not less than 0.99.
• Accuracy: recovery commonly within 80% to 120% at low ppm spike levels.
• Precision: repeatability RSD generally not more than 10% to 15% near the specification limit.
• Sensitivity: LOQ demonstrated at or below a defined fraction (for example, 10% to 30%) of each limit.
• Robustness and solution stability across the headspace analysis sequence.

Applications

Determination of residual solvents in pharmaceutical preparations supports the full product lifecycle:

• Regulatory dossier submission, including CMC sections (3.2.P.5) for new drug applications, generics, and post-approval variations.
• Routine quality control and batch release testing of finished dosage forms against registered specifications.
• Long-term, accelerated, and in-use stability studies to confirm that solvent levels do not increase or migrate during shelf life.
• Formulation and process development, including optimization of drying, coating, and granulation parameters to minimize solvent retention.
• Excipient supplier qualification and incoming material control for solvent-containing ingredients such as coating premixes and binders.
• Investigation of out-of-specification results, manufacturing deviations, and process transfer activities.
• Support of cleaning validation and equipment changeover assessments for shared solvent-handling equipment.

FAQ

Why must finished preparations be tested if the API is already controlled for residual solvents?

Finished products contain additional sources of solvents beyond the API, including excipients, film-coating systems, granulation liquids, and packaging-adjacent processes. The finished-product test verifies the total patient exposure from all components against the PDE calculated for the actual administered daily dose.

Which solvents should be included in the test panel for a finished product?

The panel should include every solvent reasonably expected to be present: solvents from the final synthetic steps of the API, solvents used in excipient manufacture, and solvents employed in formulation and coating. If such information is unavailable, a general screen for all Class 1 and Class 2 solvents is performed.

How are limits handled for high-dose products exceeding 10 g per day?

For daily doses above 10 g, Option 1 tabulated limits no longer apply. Product-specific limits are calculated as the PDE divided by the maximum daily dose, and the analytical method must be sensitive enough to quantify reliably at the tightened specification.

What sample quantity and storage conditions are required?

A typical submission requires the equivalent of several dosage units (approximately 1 to 5 g). Samples should be sealed in airtight containers with minimal headspace, protected from heat and light, and shipped promptly to prevent volatile loss before analysis.

What happens if an unlisted or unexpected solvent is detected?

The peak is first confirmed and identified, typically by two-column GC and GC-MS. The manufacturer must then either eliminate or reduce the solvent through process modification, or establish a scientifically justified acceptance limit based on toxicological data and document it in the regulatory submission.